Haisco Pharmaceutical Group Co. Ltd. has identified pyridone derivatives acting as integrin α4β7 (LPAM-1) antagonists reported to be useful for the treatment of Crohn’s disease and ulcerative colitis.

Dice Molecules SV LLC has divulged integrin α4β7 (LPAM-1) antagonists reported to be useful for the treatment of graft-vs.-host disease, type 1 diabetes, inflammatory bowel disease, colitis and primary sclerosing cholangitis.

Morphic Therapeutic Inc. has divulged integrin α4β7 (LPAM-1) antagonists reported to be useful for the treatment of inflammatory bowel disease (IBD).

Evotec International GmbH has disclosed integrin α4β7 (LPAM-1) antagonists reported to be useful for the treatment of ulcerative colitis and Crohn’s disease.

Evotec International GmbH has synthesized integrin α4β7 (LPAM-1) antagonists reported to be useful for the treatment of ulcerative colitis and Crohn’s disease.

Tibet Haisco Pharmaceutical Co. Ltd. has disclosed integrin α4β7 (LPAM-1) and/or α4β1 (ITGA4; VLA-4) antagonists reported to be useful for the treatment of inflammatory disorders.

Haisco Pharmaceutical Group Co. Ltd. has described propionic acid derivatives acting as integrin α4β7 (LPAM-1) antagonists reported to be useful for the treatment of inflammatory disorders.